Name: Can myeloma progress after an autologous stem cell transplant (ASCT)?
Uploaded: 2016-02-19T12:07:23-0800
Duration: 4 min 31 s
Description: In this week's video, Dr. Brian G.M. Durie discusses the pros and cons of an autologous stem cell transplant (ASCT). Bottom line: It is rare to become worse after ASCT, and its likely benefits need to be evaluated on a long-term basis.

In this week's video, Dr. Brian G.M. Durie discusses the pros and cons of an autologous stem cell transplant (ASCT).

Bottom line:

It is rare to become worse after ASCT, and its likely benefits need to be evaluated on a long-term basis.

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.